Multipotent Human Mesenchymal Stromal Cells Mediate Expansion of Myeloid-Derived Suppressor Cells via Hepatocyte Growth Factor/c-Met and STAT3
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Mesenchymal stromal cells (MSCs) are multilineage progenitors with immunomodulatory properties, including expansion of immunomodulatory leukocytes such as regulatory T lymphocytes (Tregs) and tolerogenic dendritic cells. We report that human MSCs can expand CD14(-)CD11b(+)CD33(+) human myeloid-derived suppressor cells (MDSCs). MSC-expanded MDSCs suppress allogeneic lymphocyte proliferation, express arginase-1 and inducible nitric oxide synthase, and increase the number of Tregs. This expansion occurs through the secretion of hepatocyte growth factor (HGF), with effects replicated by adding HGF singly and abrogated by HGF knockdown in MSCs. In wild-type mice, the liver, which secretes high levels of HGF, contains high numbers of Gr-1(+)CD11b(+) MDSCs, and injection of HGF into mice significantly increases the number of MDSCs. Expansion of MDSCs by MSC-secreted HGF involves c-Met (its receptor) and downstream phosphorylation of STAT3, a key factor in MDSC expansion. Our data further support the strong immunomodulatory nature of MSCs and demonstrate the role of HGF, a mitogenic molecule, in the expansion of MDSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 1×
“Our finding that STAT3 activation is involved in HGF-mediated MDSC expansion further supports the importance of this molecule in inflammation and cancer (Yu et al., 2009).”
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 5×
“…139 cytotoxic lymphocyte effector functions and targeting T cells by expressing the enzymes arginase 1 (ARG1) and inducible nitric oxide synthase (iNOS), both ofwhich block the production of the T cell CD3-z chain by metabolizing L-arginine (Gabrilovich and Nagaraj, 2009; Gabrilovich et al., 2012).”
InfluentialDi Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166 · cited 1×
“As exciting as these findings are, some researchers have noted that the same immunomodulatory effects of MSCs can allow for the growth of tumors (Djouad et al., 2003).”
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 2×
“Although it is clear that the tumor microenvironment is maintained by diverse cell types, the role of secreted factors other than cytokines and proinflammatory factors in the expansion of MDSCs has largely been unexplored, with the exception of vascular endothelial growth factor (Fricke et al., 2007; Shojaei et al., 2…”
Mesenchymal stromal cells: new directions
Keating, A. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.015 · Cited by 778
Klopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562 · cited 1×
“However, whether MSCs definitively enhance or inhibit tumor growth and cancer progression is still unresolved, since differences in the experimental design, cancer histologic cell type, and MSC isolation technique used can all affect the experimental outcome (Klopp et al., 2011; Yen and Yen, 2008).”
Cited by
Immune modulation by mesenchymal stem cells
Jiang, W., & Xu, J. (2020) · Cell Proliferation · doi:10.1111/cpr.12712 · Cited by 650
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 386
Transcriptional regulation of myeloid-derived suppressor cells
Condamine, T., Mastio, J., & Gabrilovich, D. I. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4ri0515-204r · Cited by 372
Wang, L.-T., Ting, C.-H., Yen, M.-L., Liu, K.-J., Sytwu, H.-K., Wu, K. K., & Yen, B. L. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0289-5 · Cited by 341
Self-citationRegmi, S., Pathak, S., Kim, J. O., Yong, C. S., & Jeong, J.-H. (2019) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2019.04.002 · Cited by 314
Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases
Zhao, Q., Ren, H., & Han, Z. (2016) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2014.12.001 · Cited by 302
Immune tolerance in liver disease
Crispe, I. N. (2014) · Hepatology · doi:10.1002/hep.27254 · Cited by 275
Mesenchymal stromal cells and the innate immune response
Le Blanc, K., & Davies, L. C. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.05.004 · Cited by 262
Galland, S., & Stamenkovic, I. (2020) · The Journal of Pathology · doi:10.1002/path.5357 · Cited by 165
Zhang, H., Lian, M., Zhang, J., Bian, Z., Tang, R., Miao, Q., Peng, Y., Fang, J., You, Z., Invernizzi, P., et al. (2018) · Hepatology · doi:10.1002/hep.29418 · Cited by 61
“The functionality of MDSCs has been primarily based on the suppression of T-cell proliferation by inducible enzymes, such as nitric oxide synthase 2/inducible nitric oxide synthase (iNOS),((6,7)) and the majority of studies involve murine models.”
Maiso, P., Mogollón, P., Ocio, E. M., & Garayoa, M. (2021) · Cancers · doi:10.3390/cancers13112542 · Cited by 48
“In the BM microenvironment, stromal cells have been shown to contribute to the expansion and activation of MDSCs through the secretion of hepatocyte growth factor (HGF) and activation of the STAT3 pathway [201].”
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials
Huang, W.-C., Li, Y.-C., Chen, P.-X., Ma, K. S.-K., & Wang, L.-T. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04127-y · Cited by 29
Metadata
- Authors
- Yen, B. L., Yen, M.-L., Hsu, P.-J., Liu, K.-J., Wang, C.-J., Bai, C.-H., & Sytwu, H.-K.
- Venue
- Stem Cell Reports
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 1
- Issue
- 2
- Pages
- 139-151
- ISSN
- 2213-6711 (ISSN-L)
- OpenAlex
- W2151087797
- Cited by
- 138
- References
- 12
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.